Skip to main content
Equibles

VRXA · Veraxa Biotech AG - Post de-SPAC · Metrics

Track VRXA — free

Use VRXA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRXA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.13 +0.00 (+0.00%) At close · Oct 5
Rebalance outlook locked
Market Cap
$199.39M
Shares
141.41M
Volume · Oct 5 154.08K Avg daily vol (3M) 396.74K

VRXA metrics

37 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.13
Market cap
$199.39M

Price action

20 metrics
Price change (1W)
-19.9%
Price change (30D)
-29.4%
Price change (3M)
-44.6%
Price change (6M)
-90.8%
Price change (YTD)
-89.4%
Price change (1Y)
-89.2%
Trailing year
Price change (5Y)
—
52-week high
$24.79
52-week low
$1.13
Change from 52-week high
-95.4%
Change from 52-week low
+0.0%
Annualized volatility
134.0%
Annualized volatility (3M)
115.2%
Beta
1.0
RSI (14D)
26.9
Price vs SMA 50
-31.3%
Price vs SMA 200
-85.7%
Avg volume (3M)
396,740
Relative volume
0.4
Average dollar volume
$870,816

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
141.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.8
reciprocal yield 17.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.03M
Total assets
$93.48M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
31
13F filer change QoQ
+31
Institutional ownership
6.8%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
$82,650
Insider-sentiment score
84 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2079109 CUSIP H9130A103 Visit website Investor relations